Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer

about

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer

Item

http://www.wikidata.org/entity/Q36028961

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical Outcomes with First-l ...... HER2- Metastatic Breast Cancer

@ast

Clinical Outcomes with First-l ...... HER2- Metastatic Breast Cancer

@en

type

Item

label

Clinical Outcomes with First-l ...... HER2- Metastatic Breast Cancer

@ast

Clinical Outcomes with First-l ...... HER2- Metastatic Breast Cancer

@en

prefLabel

Clinical Outcomes with First-l ...... HER2- Metastatic Breast Cancer

@ast

Clinical Outcomes with First-l ...... HER2- Metastatic Breast Cancer

@en

P1476

Clinical Outcomes with First-l ...... HER2- Metastatic Breast Cancer

@en

P2093

Alexander R Macalalad

http://www.w3.org/2001/XMLSchema#string

James E Signorovitch

http://www.w3.org/2001/XMLSchema#string

Peggy L Lin

http://www.w3.org/2001/XMLSchema#string

Yan Song

http://www.w3.org/2001/XMLSchema#string

Yanni Hao

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

Classical chemotherapy: mechanisms, toxicities and the therapeutic window.

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?

Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer.

Goals and objectives in the management of metastatic breast cancer.

What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?

Metastatic behavior of breast cancer subtypes.

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

P304

67-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/BCBCR.S30771

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eric Q Wu

P577

2015-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26380551

http://www.w3.org/2001/XMLSchema#string

P932

4560455

http://www.w3.org/2001/XMLSchema#string